Sanofi therapy wins Australian registration for non-relapsing secondary progressive MS

Liz Selby, Country Lead for Sanofi Australia and New Zealand, said, "Despite progress in relapsing remitting MS treatments, there remains a significant burden on people with nrSPMS who have limited treatment options to manage their disease progression." …